ORBi: Michel Olivier - Evaluation of oral corticosteroids and phosphodiesterase-4 inhibitor on the acute inflammation induced by inhaled lipopolysaccharide in human.

Reference : Evaluation of oral corticosteroids and phosphodiesterase-4 inhibitor on the acute inflam...


	Document type :	Scientific journals : Article
	Discipline(s) :	Human health sciences : Cardiovascular & respiratory systems
	To cite this reference:	http://hdl.handle.net/2268/56703

Title :	Evaluation of oral corticosteroids and phosphodiesterase-4 inhibitor on the acute inflammation induced by inhaled lipopolysaccharide in human.
Language :	English
Author, co-author :	Michel, Olivier [ > > ]
	Dentener, Mieke [ > > ]
	Cataldo, Didier [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, humaines et path. >]
	Cantinieaux, Brigitte [ > > ]
	Vertongen, Françoise [ > > ]
	Delvaux, Catherine [ > > ]
	Murdoch, Robert D [ > > ]
Publication date :	2007
Journal title :	Pulmonary Pharmacology & Therapeutics
Publisher :	Academic Press
Volume :	20
Issue/season :	6
Pages :	676-83
Audience :	International
ISSN :	1094-5539
City :	London
Country :	United Kingdom
Keywords :	[en] Corticosteroid ; PDE4-inhibitor; ; Lipopolysaccharide; ; Endotoxin; ; Inflammation; ; Asthma; ; Induced-sputum; ; Gelatinolytic activity ; Acute-phase proteins ; Neutrophils
Abstract :	[en] Background Endotoxins are pro-inflammatory substances present in the environment. In man, inhalation of its purified derivative lipopolysaccharide (LPS) induces inflammation related to macrophages and neutrophils. Corticosteroids and phosphodiesterase (PDE)-4 inhibitors have inhibiting effects on macrophages and neutrophils, respectively. This study investigated the effect of prednisolone and of the PDE-4 inhibitor cilomilast on the LPS-induced acute inflammation. Methods The study was a placebo-controlled, double-blind crossover design. On three occasions, at 2 weeks interval, 16 healthy subjects inhaled 50 μg LPS after a 6-day treatment with cilomilast (15 mg bd), prednisolone (10 mg bd) or placebo. For the assessment of the inflammatory response, induced sputum was obtained before inclusion and 6 h post-LPS while blood samples were collected before, 6 and 24 h post-LPS. Results Inhaled LPS induced an increase in sputum neutrophils (p<0.0001), logMMP-9 (p<0.05), logMMP-9/TIMP-1 (p<0.01) and logTNF-α (p<0.02). At the blood level there were significant rise in neutrophilia (p<0.001), E-selectin (p<0.02), C-reactive protein (CRP) (p<0.001) and LPS-binding protein (p<0.001). There was both a slight, but not significant, increase in body temperature and decrease in forced expiratory volume in 1 s (FEV1). Neither prednisolone nor cilomilast had protective effect on the LPS-induced airways’ inflammation. The LPS-induced CRP acute-phase protein of inflammation (0.58±0.13 and 3.52±0.41 mg/dL, before and after LPS, respectively) was significantly inhibited by a pre-treatment with prednisolone (1.39±0.32 mg/dL, p<0.01) and attenuated (2.65±0.30 mg/dL, p=0.09) with cilomilast. Conclusion In healthy subjects, while the LPS-induced airways’ inflammation was not modified either by oral prednisolone or by PDE-4 inhibitor cilomilast (at actual dosage), the LPS-induced acute phase of blood inflammation was reduced by prednisolone.
Permalink :	http://hdl.handle.net/2268/56703
DOI :	10.1016/j.pupt.2006.08.002

File(s) associated to this reference

Fulltext file(s):

	File	Commentary	Version	Size	Access
Restricted access	Michel O PPT 2007.pdf		Publisher postprint	263.06 kB	Request copy

All documents in ORBi are protected by a user license.

Dspace v1.5